- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks
U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Results
568
Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
568 companies
TransCode Therapeutics
Market Cap: US$8.1m
A biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer.
RNAZ
US$10.29
7D
0%
1Y
-95.2%
Merck
Market Cap: US$210.1b
Operates as a healthcare company worldwide.
MRK
US$85.48
7D
0.6%
1Y
-26.7%
PainReform
Market Cap: US$2.9m
A clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel.
PRFX
US$1.38
7D
-15.3%
1Y
-72.6%
Greenwich LifeSciences
Market Cap: US$156.5m
A clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania.
GLSI
US$11.46
7D
-3.9%
1Y
-14.7%
Taysha Gene Therapies
Market Cap: US$796.6m
A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
TSHA
US$2.84
7D
-4.1%
1Y
37.9%
XOMA Royalty
Market Cap: US$392.5m
Operates as a biotech royalty aggregator in the United States and the Asia Pacific.
XOMA
US$34.76
7D
1.7%
1Y
19.7%
Disc Medicine
Market Cap: US$2.1b
A clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
IRON
US$61.40
7D
2.7%
1Y
23.8%
ProPhase Labs
Market Cap: US$14.0m
Develops and commercializes novel drugs, dietary supplements, and compounds in the United States.
PRPH
US$0.33
7D
-3.8%
1Y
-86.9%
Kairos Pharma
Market Cap: US$28.0m
A clinical-stage biopharmaceutical company, develops therapeutics for cancer patients.
KAPA
US$1.41
7D
17.5%
1Y
n/a
Lexaria Bioscience
Market Cap: US$17.2m
Operates as a biotechnology company.
LEXX
US$0.89
7D
-4.6%
1Y
-75.7%
China Pharma Holdings
Market Cap: US$4.5m
Develops, manufactures, and markets pharmaceutical products for human use in the People’s Republic of China.
CPHI
US$1.42
7D
2.9%
1Y
-24.9%
MAIA Biotechnology
Market Cap: US$50.8m
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.
MAIA
US$1.50
7D
-2.6%
1Y
-48.6%
Apollomics
Market Cap: US$4.3m
A clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.
APLM
US$4.21
7D
-32.1%
1Y
-62.7%
Coherus Oncology
Market Cap: US$134.8m
A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
CHRS
US$1.19
7D
5.3%
1Y
-12.5%
Annovis Bio
Market Cap: US$45.0m
A clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
ANVS
US$2.33
7D
-4.1%
1Y
-72.2%
IO Biotech
Market Cap: US$104.1m
A clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.
IOBT
US$1.67
7D
-2.9%
1Y
67.0%
Intensity Therapeutics
Market Cap: US$13.8m
A late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States.
INTS
US$0.28
7D
-8.9%
1Y
-93.6%
Mystic Holdings
Market Cap: US$1.5m
Through its subsidiaries, engages in the cultivation, production, and wholesale of medical and recreational cannabis in Nevada, the United States.
MSTH
US$0.013
7D
0%
1Y
n/a
GT Biopharma
Market Cap: US$3.3m
A clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms.
GTBP
US$0.90
7D
-21.1%
1Y
-57.6%
Rhythm Pharmaceuticals
Market Cap: US$6.9b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$104.21
7D
3.0%
1Y
126.8%
Alpha Teknova
Market Cap: US$231.2m
Produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
TKNO
US$4.23
7D
-7.4%
1Y
-7.0%
Cocrystal Pharma
Market Cap: US$15.4m
A biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States.
COCP
US$1.50
7D
-2.9%
1Y
-12.7%
Candel Therapeutics
Market Cap: US$317.8m
A clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients.
CADL
US$5.86
7D
-1.7%
1Y
-7.1%
NextCure
Market Cap: US$13.5m
A clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer.
NXTC
US$4.93
7D
-5.6%
1Y
-72.4%
Marker Therapeutics
Market Cap: US$12.0m
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
MRKR
US$0.89
7D
-10.5%
1Y
-70.6%
Prestige Consumer Healthcare
Market Cap: US$3.3b
Develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally.
PBH
US$66.50
7D
0.1%
1Y
-10.2%
Dogwood Therapeutics
Market Cap: US$9.5m
A development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders.
DWTX
US$4.81
7D
-3.6%
1Y
5.1%
Jasper Therapeutics
Market Cap: US$45.5m
A clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.
JSPR
US$2.76
7D
-5.5%
1Y
-85.6%
Enveric Biosciences
Market Cap: US$3.7m
A biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.
ENVB
US$1.09
7D
-18.0%
1Y
-85.8%
SELLAS Life Sciences Group
Market Cap: US$202.2m
A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
SLS
US$1.83
7D
0.5%
1Y
45.2%
BioRestorative Therapies
Market Cap: US$14.7m
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
BRTX
US$1.73
7D
13.5%
1Y
11.8%
Cadrenal Therapeutics
Market Cap: US$26.5m
Operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions.
CVKD
US$12.41
7D
-9.7%
1Y
56.1%
Pasithea Therapeutics
Market Cap: US$6.0m
A clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers.
KTTA
US$0.90
7D
27.7%
1Y
-81.5%
Pulmatrix
Market Cap: US$18.0m
A clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States.
PULM
US$4.76
7D
-2.4%
1Y
129.4%
Quoin Pharmaceuticals
Market Cap: US$4.3m
A late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States.
QNRX
US$7.60
7D
3.1%
1Y
-68.0%
Shuttle Pharmaceuticals Holdings
Market Cap: US$3.5m
A clinical stage pharmaceutical company, develops novel therapies to cure cancers.
SHPH
US$3.38
7D
-0.9%
1Y
-93.8%